Back to Health

What Does the Research Say About Efavirenz?

What Does the Research Say About Efavirenz?
Bareback Guide 27 May 2026

Efavirenz has an enormous evidence base, largely because it served as the comparator in the trials of nearly every drug that replaced it. Those same trials are the reason it was replaced.

What established it?

Trials in the late 1990s and early 2000s showed efavirenz-based combinations achieving durable viral suppression, outperforming several alternatives of the era. It became the recommended first-line option in guidance worldwide.

What did the comparative trials show?

Studies against dolutegravir, raltegravir, rilpivirine and doravirine consistently found similar or slightly lower suppression on efavirenz, driven not by virological failure but by people stopping the drug.

Why were people stopping?

Neuropsychiatric adverse events, overwhelmingly. Dizziness, abnormal dreams, insomnia and impaired concentration were reported far more frequently than on the comparators, and discontinuation for those reasons was substantially higher.

What about depression and suicidality?

An analysis of pooled trial data identified a higher rate of suicidality among efavirenz recipients compared with alternatives. Other analyses have found the association weaker. The signal was strong enough to influence guidance and to warrant caution in people with existing mental health difficulties.

What did ENCORE1 show?

That a reduced 400mg dose was non-inferior to the standard 600mg dose for viral suppression, with fewer side effects. That finding led to the reduced dose being adopted in some settings, particularly where cost matters.

Why has that not been universal?

Partly inertia, partly because the reduced dose has less evidence in specific groups such as people taking rifampicin. It remains worth asking about if side effects are the issue and a switch is not straightforward.

What about genetic variation?

Efavirenz is cleared by the enzyme CYP2B6, and common genetic variants substantially reduce its activity. People carrying those variants reach much higher drug levels at the same dose and experience more side effects. The variants are more common in some African and Asian populations.

Does that get tested for?

Not routinely in the UK. It explains a great deal of the variation in how people experience the drug, and it has been more useful as an explanation than as a practical test.

What about lipids?

Efavirenz raises cholesterol and triglycerides, consistently and in direct comparisons. This contributes to cardiovascular risk over years of treatment and is one of the arguments for switching people who have been on it long term.

What about pregnancy?

Early animal data prompted concern about birth defects, and large human datasets did not confirm an increased risk. Efavirenz has been used extensively in pregnancy internationally, and the earlier caution was withdrawn.

What about vitamin D and bone?

Efavirenz lowers vitamin D levels through enzyme induction, which has been observed consistently. The clinical significance is modest and it is a recognised finding rather than a major concern.

What about switching studies?

People switched from efavirenz to newer regimens while suppressed have maintained suppression, with improvements in sleep, mood and lipids. This is the evidence base for moving long-term patients across.

What does real-world data show?

Broadly consistent, with very high global usage and a well-documented pattern of discontinuation for tolerability rather than failure.

Where can you read the evidence yourself?

NAM aidsmap summarises HIV research reliably, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and considerably more useful than a general search.

How should you read a headline about it?

Carefully. Reports about antiretrovirals often describe single studies, early findings or practice in other countries. Checking a claim against NAM aidsmap, or asking your clinic, is quicker than assessing the study design yourself.

Do guidelines change quickly?

Deliberately slowly. Recommendations shift when several studies point the same way rather than after one result. If something you read about efavirenz seems to contradict what you were told, ask before acting on it.

What has not been established?

Outcomes over several decades, in most cases, simply because the follow-up does not yet exist. That is a reason monitoring continues rather than a warning, and it applies to almost every modern antiretroviral.